Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Company Analysis

Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Company Analysis

Global Non-Small Cell Lung Cancer (NSCLC) Market will reach US$ 25.71 Billion in 2027. Globally, lung cancer is one of the most frequent types of cancer, with two distinct subtypes. The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC). Furthermore, lung cancer, as one of the most common malignancies in the world, is responsible for a considerable number of deaths globally. As a result of the expanding frequency and incidence of non-small cell lung cancer across all demographics and age categories, demand for non-small cell lung cancer therapies has increased.

COVID-19 Impact on Non-Small Cell Lung Cancer Treatment (NSCLC) Industry:

Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic. Even for patients who were non-COVID-19, the disturbance of regular hospital services, such as imaging and treatment appointments, had a significant impact on the physical and mental well-being of these patients. The stress placed on the availability of medical resources and hospitals has reduced the clinical admissions to most other departments, including oncology departments. Consequently, the benefits some cancer patients could have received have been compromised due to treatment delay declining the market in 2020.

Worldwide Non-Small Cell Lung Cancer (NSCLC) Market Size has reached US$ 17.75 Billion in 2021

The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries. Other reasons contributing to the expansion of the non-small cell lung cancer treatments market include an increase in the proportion of smokers and exposure to toxins such as asbestos. According to our estimates, the Non-Small Cell Lung Cancer (NSCLC) Market will grow at a 6.4% CAGR from 2021 to 2027.

Adenocarcinoma Is the Most Prevalent Segment Histologically:

Our report classified the histological segment into three categories: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Compared to the other two forms, adenocarcinoma is the most common and is found in the cells responsible for mucous secretion in the outer lung sections. Furthermore, Squamous Cell Carcinoma, located in the squamous cells near the bronchus in the middle of the lungs, is one of the fastest expanding segments in the market. Large cell carcinoma, also known as undifferentiated carcinoma, can develop in any section of the lungs, is the fastest-growing, and is the most difficult to cure.

Immunotherapy Market Share is Estimated to Be the Largest:

By treatment, immunotherapy is expected to have the most significant market share. According to our estimates, the targeted therapy category will grow during the projection period. The increasing number of product launches, particularly in the immunotherapy area, is credited with the market domination. Immunotherapy is currently being used more widely in emerging countries, owing to improved patient outcomes resulting from effective treatment.

Regional Analysis:

In our report, we have examined the regions like North America, Europe, Asia-Pacific, Rest of The World. Lung cancer is becoming more common, and innovative therapies and are becoming more widely used, making the North America, Europe & Asia Pacific the most powerful region worldwide. Due to a rise in lung cancer diagnoses, India and China in the Asia Pacific region are seeing growth in NSCLC therapies. Chemotherapy is the most common kind of treatment in these underdeveloped countries. However, advanced immunotherapies and targeted medicines are seeing rising adoption and investment in nations like United States, Germany, United Kingdom, and Japan.

Key Market Players:

Our report examines AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & Co Inc., Novartis, and Pfizer Inc. as leading players in the Non-Small Cell Lung Cancer Treatment (NSCLC) Market. The majority of significant market players are also concentrating on continuous advancements in advanced therapies and improving the efficacy of existing medicines. These businesses are receiving product approvals as well.

Renub Research latest report “Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast By Histology Type (Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma), Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor), End User (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics, Others), Region (North America, Europe, Asia-Pacific, Rest of The World), Companies (AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & co Inc., Novartis, Pfizer Inc.)” provides a detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) Industry.

Histology Type - Market has been covered from 3 viewpoints:

1. Adenocarcinoma
2. Squamous Cell Carcinoma
3. Large Cell Carcinoma

Treatment Type - Market has been covered from 5 viewpoints:

1. Chemotherapy
2. Immunotherapy
3. Radiation Therapy
4. Surgery
5. Targeted Therapy Drugs

Drug Class - Market has been covered from 6 viewpoints:

1. Angiogenesis Inhibitor
2. Epidermal Growth Factor Receptor Blocker
3. Kinase Inhibitor
4. Microtubule Stabilizer
5. Folate Antimetabolites
6. PD-1/ PD-L1 Inhibitor

End User - Market has been covered from 4 viewpoints:

1. General Medical & Surgical Hospitals
2. Specialty Hospitals
3. Clinics
4. Others

Region - Market has been covered from 4 viewpoints:

1. North America
2. Europe
3. Asia-Pacific
4. Rest of The World

Company Insights:
Overview
Recent Development
Revenue

Key Players:

1. AbbVie Inc.
2. Astellas Pharma
3. AstraZeneca
4. Avid Bioservices Inc.
5. Bayer Healthcare
6. Biogen Inc.
7. Blueprint Medicines Corp
8. Eli Lilly and Company
9. Merck & co Inc.
10. Novartis
11. Pfizer Inc.